收费全文 | 108篇 |
免费 | 7篇 |
儿科学 | 5篇 |
妇产科学 | 1篇 |
基础医学 | 19篇 |
临床医学 | 6篇 |
内科学 | 37篇 |
神经病学 | 3篇 |
特种医学 | 1篇 |
外科学 | 5篇 |
综合类 | 2篇 |
预防医学 | 4篇 |
眼科学 | 1篇 |
药学 | 25篇 |
肿瘤学 | 6篇 |
2022年 | 3篇 |
2021年 | 1篇 |
2020年 | 1篇 |
2018年 | 1篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2015年 | 1篇 |
2014年 | 1篇 |
2013年 | 8篇 |
2012年 | 6篇 |
2011年 | 5篇 |
2009年 | 1篇 |
2008年 | 2篇 |
2007年 | 6篇 |
2006年 | 7篇 |
2005年 | 8篇 |
2004年 | 14篇 |
2003年 | 11篇 |
2002年 | 6篇 |
2001年 | 5篇 |
1999年 | 3篇 |
1998年 | 2篇 |
1997年 | 2篇 |
1996年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 2篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1983年 | 1篇 |
1979年 | 1篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1971年 | 1篇 |
Acromegaly is a severe chronic endocrine disease. Achieving biochemical control often needs a multimodal treatment approach, including prolonged medical treatment. Aim of the study is to evaluate the burden of treatment direct costs with respect to the different therapeutic strategies, disease control, and follow-up length.
MethodsSingle center retrospective study on 73 acromegaly patients. Costs of acromegaly treatments were computed based on a detailed revision of patients’ clinical charts.
ResultsMedian total treatment cost/patient was €47,343 during the entire follow-up (8 years), while median treatment cost/patient/year was €6811. The majority of patients received medical therapy (71/73, 97.3%). Median cost for first-line medical treatment (first-generation somatostatin receptor ligands) was lower compared to second-line treatments (pegvisomant monotherapy or combination therapies), considering both total (€22,824 vs €76,140; p?<?0.001), and yearly cost/patient (€4927 vs €9161; p?<?0.001). Sixty patients (82.2%) reached biochemical control at last follow-up (IGF-1?≤?1 xULN). The percentage of patients treated with first- or second-line medical therapies was comparable between controlled and uncontrolled patients (p?=?1.000), and the yearly cost/patient did not significantly differ between the two groups (€6936 vs €6680; p?=?0.829). Follow-up duration was significantly longer in controlled patients compared to the uncontrolled ones (8.7 vs 3.5 years; p?=?0.019).
ConclusionsDirect costs for the management of acromegaly have a significant burden on the healthcare systems. However, more than 80% of our patients reached biochemical control using multimodal approaches. Treatment modalities and yearly costs did not significantly differ between controlled and uncontrolled patients, while follow-up length represented a major determinant of biochemical outcome.
相似文献